Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus Not Currently Treated With Antidiabetic Therapy

Completed · Phase 3 · Has a placebo group

Conditions studied: Type 2 Diabetes Mellitus

In brief

Primary Objective: To demonstrate the superiority of Sotagliflozin 400 milligrams (mg) versus placebo on hemoglobin A1c (HbA1c) reduction in participants with type 2 diabetes (T2D) who have inadequate glycemic control on diet and exercise. Secondary Objectives: * To compare Sotagliflozin 400 mg versus placebo based on: * Change from baseline in 2-hour postprandial glucose (PPG) following a mixed meal. * Change from baseline in fasting plasma glucose (FPG). * Change from baseline in systolic blood pressure (SBP) for participants with baseline SBP ≥130 millimeter per mercury (mmHg). * Change from baseline in SBP for all participants. * Change from baseline in body weight. * Proportion of participants with HbA1c \<6.5%, \<7.0%. * To compare Sotagliflozin 200 mg versus placebo based on: * Change from baseline in HbA1c. * Change from baseline in 2-hour postprandial glucose (PPG) following a mixed meal. * Change from baseline in body weight. * Change from baseline in SBP for all participants. * To evaluate the safety of Sotagliflozin 400 and 200 mg versus placebo.

Key facts

Study ID

NCT02926937

Run by

Lexicon Pharmaceuticals

People needed

399

Starts

2016-11-11

Expected to finish

2019-05-17

Last updated by the study team

2021-06-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants (male and female) with T2D, who are treated with diet and exercise only during the 12 weeks prior to screening.
• Signed written informed consent.

You may not qualify if…

• Age <18 years at Screening or < legal age of majority, whichever is greater.
• Type 1 diabetes mellitus.
• Body Mass Index (BMI) ≤20 or >45 kilogram per meter square (kg/m\^2) at Screening.
• Hemoglobin A1c (HbA1c) <7% or >10% via central laboratory test at Screening.
• Fasting plasma glucose (FPG) >15 millimole per liter (mmol/L) (270 milligram per deciliter [mg/dL]) measured by the central laboratory at screening (Visit 1) and confirmed by a repeat test (>15 mmol/L [270 mg/dL]) before randomization.
• Women of childbearing potential not willing to use highly effective contraceptive method(s) of birth control during the study treatment period and the follow up period or who are unwilling or unable to be tested for pregnancy during the study.
• Treated with an antidiabetic pharmacological agent within the 12 weeks prior to the Screening Visit.
• Previous use of any types of insulin for >1 month (at any time, except for treatment of gestational diabetes).
• History of gastric surgical procedure including gastric banding within 3 years before the Screening Visit.
• History of diabetic ketoacidosis or nonketotic hyperosmolar coma within 12 weeks prior to the Screening Visit.
• Mean of 3 separate blood pressure measurements >180 millimeter of mercury (mmHg) (systolic) or >100 mmHg (diastolic).
• History of hypertensive emergency within 12 weeks prior to Screening.
• Participants with severe anemia, severe cardiovascular (including congestive heart failure New York Heart Association [NYHA] IV), respiratory, hepatic, neurological, psychiatric, or active malignant tumor or other major systemic disease or participants with short life expectancy that, according to the Investigator, will preclude their safe participation in this study, or will make implementation of the protocol or interpretation of the study results difficult.
• Aspartate aminotransferase and/or alanine aminotransferase: >3 times the upper limit of the normal laboratory range.
• Total bilirubin: >1.5 times the upper limit of the normal laboratory range (except in case of Gilbert's syndrome).
• Use of systemic glucocorticoids (excluding topical or ophthalmic application or inhaled forms) for more than 10 consecutive days within 90 days prior to the Screening Visit.
• Participants who has taken other investigational drugs or prohibited therapy for this study within 12 weeks or 5 half-lives from screening or randomization, whichever is longer. Current enrollment in any other clinical study involving an investigational study treatment or any other type of medical research.
• Pregnant (confirmed by serum pregnancy test at Screening) or breastfeeding women.
• Severe renal disease as defined by estimated glomerular filtration rate (eGFR) of <30 millimeter per minute (mL/min)/1.73 meter square (m\^2)² at screening by the 4 variable Modification of Diet in Renal Disease (MDRD) equation.
• Participant is unwilling or unable to perform self-monitoring of blood glucose (SMBG), complete the participants diary, or comply with study visits and other study procedures as required per protocol.
• Lower extremity complications (such as skin ulcers, infection, osteomyelitis and gangrene) identified during the Screening period, and still requiring treatment at Randomization.
• The above information is not intended to contain all considerations relevant to a Participant potential participation in a clinical trial.

Where it is running

• Investigational Site Number 8401026 — Tucson, Arizona, United States
• Investigational Site Number 8401028 — Anaheim, California, United States
• Investigational Site Number 8401057 — Canoga Park, California, United States
• Investigational Site Number 8401058 — Garden Grove, California, United States
• Investigational Site Number 8401029 — Hawaiian Gardens, California, United States
• Investigational Site Number 8401017 — Huntington Park, California, United States
• Investigational Site Number 8401056 — Long Beach, California, United States
• Investigational Site Number 8401013 — Long Beach, California, United States
• Investigational Site Number 8401063 — Los Angeles, California, United States
• Investigational Site Number 8401011 — Los Angeles, California, United States
• Investigational Site Number 8401022 — Montclair, California, United States
• Investigational Site Number 8401039 — Norwalk, California, United States
• Investigational Site Number 8401035 — San Dimas, California, United States
• Investigational Site Number 8401025 — Tustin, California, United States
• Investigational Site Number 8401015 — Van Nuys, California, United States
• Investigational Site Number 8401031 — Denver, Colorado, United States
• Investigational Site Number 8401060 — Northglenn, Colorado, United States
• Investigational Site Number 8401024 — Bradenton, Florida, United States
• Investigational Site Number 8401040 — Clearwater, Florida, United States
• Investigational Site Number 8401014 — Daytona Beach, Florida, United States
• Investigational Site Number 8401007 — Hialeah, Florida, United States
• Investigational Site Number 8401046 — Homestead, Florida, United States
• Investigational Site Number 8401018 — Miami, Florida, United States
• Investigational Site Number 8401008 — Miami, Florida, United States
• Investigational Site Number 8401049 — Tucson, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.